BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld
See today's BioWorld Asia
Home
» Lianbio says hit-and-miss for co-primary endpoints in Xdemvy’s China trial
To read the full story,
subscribe
or
sign in
.
Lianbio says hit-and-miss for co-primary endpoints in Xdemvy’s China trial
Oct. 31, 2023
By
Marian (YoonJee) Chu
No Comments
Lianbio Co. Ltd. announced mixed phase III top-line results on Oct. 30 for its in-licensed Demodex blepharitis treatment called TP-03, with the U.S. FDA-approved eyedrop hitting just one co-primary endpoint in the Libra trial on Chinese patients.
BioWorld
BioWorld Asia
Clinical
Ocular
China